[3aR-(3aα,4β,5α,7β,7aα)]-(2-methoxyethoxy)methyl 2-(4-cyano-3-(trifluoromethyl)phenyl)hexahydro-4,7-dimethyl-1,3-dioxo-4,7-epoxy-1H-isoindole-5-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: [3aR-(3aα,4β,5α,7β,7aα)]-(2-methoxyethoxy)methyl 2-(4-cyano-3-(trifluoromethyl)phenyl)hexahydro-4,7-dimethyl-1,3-dioxo-4,7-epoxy-1H-isoindole-5-carboxylate
• 化学式: C₂₃H₂₃F₃N₂O₇
• 分子量: 496.44
• InChiKey: HTANSGKHUNBSEE-DUNUVARXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.41
• 重原子数：
  35.0
• 可旋转键数：
  7.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  115.16
• 氢给体数：
  0.0
• 氢受体数：
  8.0

反应信息

• 作为反应物：
  描述：

  [3aR-(3aα,4β,5α,7β,7aα)]-(2-methoxyethoxy)methyl 2-(4-cyano-3-(trifluoromethyl)phenyl)hexahydro-4,7-dimethyl-1,3-dioxo-4,7-epoxy-1H-isoindole-5-carboxylate 在 盐酸 、 叠氮磷酸二苯酯 、 水 、 三乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 21.0h， 生成 BMS-641988
  参考文献：
  名称：

  Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer

  摘要：

  BMS-641988 (23) is a novel, nonsteroidal androgen receptor antagonist designed for the treatment of prostate cancer. The compound has high binding affinity for the AR and acts as a functional antagonist in vitro. BMS-641988 is efficacious in multiple human prostate cancer xenograft models, including CWR22-BMSLD1 where it displays superior efficacy relative to bicalutamide. Based on its promising preclinical profile, BMS-641988 was selected for clinical development.

  DOI：

  10.1021/acsmedchemlett.5b00173
• 作为产物：
  描述：

  4-氨基-2-三氟甲基苯甲腈 在 palladium 10% on activated carbon 、 氢气 、 溶剂黄146 作用下， 以 乙醇 、 正庚烷 、 乙酸乙酯 为溶剂， 反应 1.5h， 生成 2-methoxyethoxymethyl (3aS,4S,5S,7S,7aR)-2-[4-cyano-3-(trifluoromethyl)phenyl]-4,7-dimethyl-1,3-dioxo-3a,5,6,7a-tetrahydro-4,7-epoxyisoindole-5-carboxylate 、 [3aR-(3aα,4β,5α,7β,7aα)]-(2-methoxyethoxy)methyl 2-(4-cyano-3-(trifluoromethyl)phenyl)hexahydro-4,7-dimethyl-1,3-dioxo-4,7-epoxy-1H-isoindole-5-carboxylate
  参考文献：
  名称：

  Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer

  摘要：

  BMS-641988 (23) is a novel, nonsteroidal androgen receptor antagonist designed for the treatment of prostate cancer. The compound has high binding affinity for the AR and acts as a functional antagonist in vitro. BMS-641988 is efficacious in multiple human prostate cancer xenograft models, including CWR22-BMSLD1 where it displays superior efficacy relative to bicalutamide. Based on its promising preclinical profile, BMS-641988 was selected for clinical development.

  DOI：

  10.1021/acsmedchemlett.5b00173